WINTON GROUP Ltd Sells 65,754 Shares of Integra LifeSciences Holdings Corporation $IART

WINTON GROUP Ltd reduced its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 47.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,799 shares of the life sciences company’s stock after selling 65,754 shares during the quarter. WINTON GROUP Ltd owned 0.09% of Integra LifeSciences worth $1,029,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IART. Rubric Capital Management LP increased its holdings in Integra LifeSciences by 58.4% during the 2nd quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company’s stock worth $90,233,000 after purchasing an additional 2,710,262 shares in the last quarter. Paradigm Capital Management Inc. NY lifted its holdings in shares of Integra LifeSciences by 57.5% in the second quarter. Paradigm Capital Management Inc. NY now owns 2,181,500 shares of the life sciences company’s stock valued at $26,767,000 after purchasing an additional 796,300 shares in the last quarter. Soleus Capital Management L.P. lifted its holdings in shares of Integra LifeSciences by 29.4% in the second quarter. Soleus Capital Management L.P. now owns 1,387,818 shares of the life sciences company’s stock valued at $17,029,000 after purchasing an additional 315,614 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Integra LifeSciences by 9.2% during the third quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock worth $45,634,000 after buying an additional 267,134 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Integra LifeSciences during the second quarter worth about $2,960,000. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Stock Up 0.1%

Shares of NASDAQ:IART traded up $0.01 during midday trading on Friday, reaching $9.18. The company had a trading volume of 77,526 shares, compared to its average volume of 754,611. Integra LifeSciences Holdings Corporation has a 1-year low of $8.91 and a 1-year high of $23.27. The stock has a market cap of $715.18 million, a PE ratio of -1.37 and a beta of 1.02. The company has a quick ratio of 1.46, a current ratio of 2.54 and a debt-to-equity ratio of 1.66. The business’s 50 day moving average price is $11.47 and its 200 day moving average price is $12.93.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Thursday, February 26th. The life sciences company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.79 by $0.04. The firm had revenue of $434.93 million during the quarter, compared to analysts’ expectations of $429.62 million. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The business’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.97 earnings per share. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. Research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Wells Fargo & Company dropped their target price on Integra LifeSciences from $13.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Friday, February 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Integra LifeSciences in a research report on Monday, December 29th. Wall Street Zen cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Citigroup lowered their price objective on shares of Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating on the stock in a report on Wednesday. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Reduce” and a consensus price target of $14.40.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.